• 12/18/2012

    PAION received milestone payment of USD 3 million from Ono Pharmaceutical due to enrolment of first patient into the Phase II/III study with Remimazolam in Japan

  • 11/05/2012

    PAION AG: New Supervisory Board Member appointed

  • 11/05/2012

    PAION's Partner ONO Pharmaceutical announced today initiation of a Phase II/III StudY with short-acting anaesthetic/sedative Remimazolam (ONO's Development code: ONO-2745) in Japan

  • 08/08/2012

    PAION AG reports financial results for the first half year 2012

  • 08/08/2012

    PAION realizes first step of strategic realignment: Purchase of Remifentanil distribution rights for Germany

  • 08/01/2012

    Article about Remimazolam has been chosen as article of the month by Anesthesia & Analgesia (A&A)

  • 07/18/2012

    PAION AG grants license to YICHANG Humanwell for Remimazolam in China

  • 07/09/2012

    Preclinical Efficacy of Solulin in radiation injury confirmed in US/german Research collaboration and published in “Nature Medicine“

  • 07/02/2012

    PAION Deutschland GmbH receives a Grant worth EUR 0.7 million from the Federal Ministry of Education and Reserach (BMBF) for research into the potential of thrombomodulin - mutants

  • 05/14/2012

    Results of Phase II Study of Remimazolam (ONO-2745/CNS 7056), a Short-acting General Anesthetic

  • 04/17/2012

    PAION receives Euro 2.1 Million through the sale of Desmoteplase by completion of data and know-how transfer from H. Lundbeck A/

  • 03/22/2012

    PAION signed exclusive option agreement with Yichang for Remimazolam in China

  • 03/14/2012

    PAION AG reports financial results for the full year 2011

  • 02/28/2012

    PAION Receives Euro 20 Million for Sale of Remaining Desmoteplase Rights to H. Lundbeck A/S